Literature DB >> 29325952

Endovascular Treatment of Intracranial Aneurysms Concomitant with Severe Adjacent Atherosclerotic Stenosis.

Bu-Lang Gao1, Zhao-Shuo Li1, Tian-Xiao Li2, Jiang-Yu Xue1, Guang Feng1, Zi-Liang Wang1, Wei-Xing Bai1, Tong-Yuan Zhao1, Xiao-Dong Liang1.   

Abstract

PURPOSE: To investigate the effect and safety of endovascular treatment of intracranial aneurysms concomitant with severe adjacent atherosclerotic stenosis.
MATERIALS AND METHODS: Twenty-six patients with aneurysms and adjacent stenosis were prospectively enrolled. The characteristics of the aneurysm, parent artery, atherosclerotic stenosis and endovascular treatment methods were analyzed.
RESULTS: All aneurysms were successfully embolized (100%), with stent-assisted coiling in 14 (53.8%) cases, coiling alone in 10 (38.5%), double microcatheter coiling in 1 (3.8%), and balloon-assisted coiling in the remaining 1 (3.8%). Immediately after embolization, complete occlusion was achieved in 10 cases (38.5%), nearly complete occlusion in 6 (23.1%) and non-complete occlusion in 10 (38.5%). Ten aneurysms were type I and were managed with coiling alone in 8 cases and stent-assisted coiling in the remaining 2 cases, with complete occlusion achieved in 6 cases (60%), nearly complete in 2 (20%), and noncomplete in the other 2 (20%). Sixteen aneurysms were type II and treated with stent-assisted coiling in 12 cases (75%), single coiling in 2 (12.5%), double microcatheters in 1 (6.3%), and balloon-assisted coiling in the remaining aneurysm (6.3%). Aneurysm occlusion was complete in 4 cases (25%), nearly complete in 4 (25%), and noncomplete in the other 8 (50%). Clinical follow-up of 2 months to 5 years (mean 26 ± 11 months) demonstrated no rebleeding, with the modified Rankin scale score of 0-2 in 20 patients, 3 in 4, and 6 in the remaining 2.
CONCLUSIONS: Intracranial aneurysms concomitant with severe adjacent atherosclerotic stenosis can be successfully treated endovascularly, and careful evaluation of the characteristics of the aneurysm, parent artery, stenosis and collateral circulation can help reducing complications.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angioplasty; Atherosclerotic stenosis; Endovascular treatment; Intracranial aneurysm; Stenting

Mesh:

Year:  2018        PMID: 29325952     DOI: 10.1016/j.wneu.2018.01.027

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Endovascular Treatment of Small Ruptured Intracranial Aneurysms (<5 mm) : Long-term Clinical and Angiographic Outcomes and Related Predictors.

Authors:  Fei Peng; Xin Feng; Xin Tong; Baorui Zhang; Luyao Wang; Erkang Guo; Peng Qi; Jun Lu; Zhongxue Wu; Daming Wang; Aihua Liu
Journal:  Clin Neuroradiol       Date:  2019-11-06       Impact factor: 3.649

2.  Microwire navigation and microcatheter positioning by balloon manipulation for the treatment of intracranial aneurysms: A pilot study.

Authors:  Ali Burak Binboga; Mehmet Onay; Cetin Murat Altay
Journal:  Indian J Radiol Imaging       Date:  2021-01-13

Review 3.  Unruptured cerebral aneurysms in elderly patients: key challenges and management.

Authors:  Nicholas Caffes; Nicole Wenger; Gregory Cannarsa; Jeffrey Oliver; Chimdiya Onwukwe; Dheeraj Gandhi; J Marc Simard
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

4.  Independent predictors and risk score for intraprocedural rupture during endovascular treatment of small ruptured intracranial aneurysms (<5 mm).

Authors:  Fei Peng; Xin Feng; Xiaoxin He; Hao Niu; Hong Zhang; Xin Tong; Baorui Zhang; Jiaxiang Xia; Xuge Chen; Boya Xu; Peng Qi; Jun Lu; Daming Wang; Aihua Liu
Journal:  Front Neurol       Date:  2022-08-24       Impact factor: 4.086

5.  Intervals of endovascular treatment for coincidental non-adjacent unruptured aneurysms in patients with symptomatic intracranial atherosclerotic stenosis.

Authors:  Hengwei Jin; Jing Wang; Xiangyu Meng; Youxiang Li; Hongwei He
Journal:  Front Neurol       Date:  2022-09-23       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.